Key result
Age >=65 linked to ~1.1-point lower mean INR at warfarin-related major bleeding.
Why the study?
The risk of major bleeding associated with warfarin increases with both rising INR and advanced age, motivating an evaluation of the association between age and INR at the time of warfarin-related major bleeding.
Does advanced age lower the INR threshold at which major bleeding occurs in patients treated with warfarin?
Observational (n=66)
Yes
Does advanced age lower the INR threshold at which major bleeding occurs in patients treated with warfarin?
Older patients experience warfarin-related major bleeding at significantly lower INR levels than younger patients, suggesting a need for more careful management of anticoagulation in this population.
Answers are grounded in this paper and cite their sources.
Patients ≥65 years may experience major bleeding at lower INRs; hypothesis-generating and requires prospective validation before guiding targets.
Study Objectives. Because the risk of major bleeding associated with warfarin increases with increasing international normalized ratio (INR) as well as with advanced age, we evaluated the association between age and INR in patients with major bleeding events related to anticoagulation with warfarin. Design. Retrospective record review. Setting. Two university‐affiliated anticoagulation clinics. Patients. Sixty‐six patients (mean age 61.2 yrs, range 21–90 yrs) receiving warfarin therapy who experienced major bleeding, defined as bleeding requiring hospitalization, during a 20‐month index period. Measurements and Main Results. In patients aged 65 years or older, the mean INR at the time of a major bleeding event was significantly lower than that in patients younger than 65 years (INR 3.1 vs 4.2, respectively; p=0.01). For every 1‐year increase in age, mean INR at the time of a major bleeding event decreased by 0.03 (p=0.02). Conclusion. Patients aged 65 years or older experience warfarin‐related major bleeding events at a mean INR 1.1 units lower (95% confidence interval −1.9 to −0.27) than patients younger than 65 years. Older patients may require more aggressive management of overanticoagulation to minimize the risk of major bleeding.
No takes yet. Share an insight, caveat, or question.
Wittkowsky et al. (2004) conducted an observational in Warfarin-related major bleeding (n=66). Age >= 65 years on warfarin vs. Age < 65 years on warfarin was evaluated on Mean INR at the time of a major bleeding event (MD -1.1, 95% CI -1.9 to -0.27, p=0.01). Patients aged >=65 years had warfarin-related major bleeding at a lower mean INR than those <65 years.
Synapse has enriched 10 related papers. Consider them for comparative context: